Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already cover read-only and non-destructive behavior. The description adds extra transparency by disclosing the cost ($0.02/call), the official openFDA data source, and what data is returned (application status, sponsor, latest submission, recall details). This goes beyond the annotations' safety profile, though it doesn't mention rate limits or update frequency.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is compact and front-loaded, with the core purpose in the first sentence. Every sentence provides value: data source, output details, and cost. No filler or redundancy.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Although there is no output schema, the description explains the kind of return data (application status, sponsor, submission, recall details). For a moderate-complexity tool with a well-described schema, this is sufficient context to understand what the tool does and returns. It doesn't fully explain how 'watch' behaves (e.g., alert vs. snapshot), but that's a minor gap.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema already provides 100% description coverage for parameters, including queries, limit, dataset, and maxConcurrency. The description adds no additional parameter-specific meaning; it only restates that queries are drug/company names (already in the schema). Thus the baseline score of 3 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool's purpose with a specific verb ('Watch') and resource ('drugs or companies') for FDA approvals and recalls. It distinguishes itself from sibling tools by specifying the FDA domain and mentioning 'Official openFDA data', making its unique scope evident.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description provides clear context for when to use the tool: monitoring FDA approvals and recalls. It mentions the official data source, free access, and per-call cost, which helps the agent decide if it fits the user's needs. However, it does not explicitly state when not to use it or mention alternatives among sibling tools.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.